bluebird Q2 results, updates

 Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 16 patient starts across both programs to date –

- Biologics License Application (BLA) for lovo-cel for sickle cell disease accepted for FDA priority review; PDUFA goal date December 20, 2023 -

- Ended quarter with $291M in cash, cash equivalents, marketable securities and restricted cash –

- Management to host conference call on Q2 earnings and commercial launch progress today August 8, 2023 at 8:00AM ET -

bluebird will hold a conference call to discuss second quarter financial results and commercial launch progress on Tuesday, August 8 at 8:00 am ET.

To access the call via telephone, please register at this link https://register.vevent.com/register/BI4fa1d86317c74333813f6827624e43ae to receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

https://finance.yahoo.com/news/bluebird-bio-reports-second-quarter-110000706.html